Lenvatinib — a multitargeted tyrosine kinase inhibitor — plus the PD-1 inhibitor pembrolizumab (Keytruda, Merck) is standard treatment for women with advanced, mismatch repair-proficient ...

Keytruda has struggled to make an impact in ... like Eisai's Lenvima (lenvatinib). The issue with TKIs is that their effects tend to be short-lived, as tumours develop random mutations in target ...

Merck and Eisai got an accelerated okay from the FDA for the combination of PD-1 inhibitor Keytruda (pembrolizumab) with Eisai’s targeted therapy Lenvima (lenvatinib) in September 2019 based on ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity. Decrease or stabilization in metastatic lesions ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

There are concerns about Merck’s ability to successfully navigate the loss of exclusivity period for its blockbuster drug, Keytruda, and potential competition for Keytruda. With a weak fourth ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the ...